Dose adjustments for drug-drug interactions and adverse events, tumor lysis syndrome (TLS) risk assessment, prophylaxis and monitoring are important components of venetoclax management.1 Depending on a patient’s risk for tumor lysis syndrome (TLS), some patients may require hospital admission during the dose titration process.2 The hospital admission presents its own set of challenges and effective communication between the oncology pharmacist, nurse, lab technicians, hematologist, and the patient is necessary to make sure the recommended administration guidelines and lab monitoring are followed and ensure patient safety and best outcomes.